Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • RSS
  • Contact us

10 September 2010


The Pharma Letter
  • Home
  • 30 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Asenapine Sublingual Tablets Articles

Merck & Co’s integrated pipeline has over 20 drugs and vaccines in late-stage development

2 March 2010

Emerging oral atypical antipsychotics will garner only limited uptake in schizophrenia market

25 February 2010

Merck & Co rises 2.3% as it beats 4th quarter 2009 sales forecast, boosted by Schering-Plough

17 February 2010

US FDA clears new indications for B-MS/Otsuka’s Abilify and Pfizer’s Geodon

23 November 2009

Schering-Plough’s income dips in 3rd quarter 2009, hit by charges

23 October 2009

Schering-Plough gets US approval for Saphris

17 August 2009

Pipeline antipsychotic drugs to drive next market evolution

7 August 2009

FDA Committee backs Schering-Plough’s Saphris

3 August 2009

Merck & Co makes agreed $41.1B bid to acquire Schering-Plough

16 March 2009

S-P responds to FDA's questions on Saphris NDA

2 March 2009

FDA requests more existing data on S-P's Saphris before approval

19 January 2009

S-P claims superior pipeline to competitors; new drugs could make $7B in next 4 years

8 December 2008

S-P's Saphris effective in schizophrenia relapse

1 December 2008

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Ono Pharma buys Japanese rights to two cancer drugs in $340 million deal with Onyx
  • GlaxoSmithKline sells Croatian research center to Galapagos, names new CFO and enters supply deal with Lonza; EMEA update on Avandia and Pandemrix
  • Wyeth/Pfizer accused of using ghostwritten articles to overstate benefits of HRT
  • China’s liver cancer drug market forecast to nearly triple to $144 million in 2014
  • International sales rep quality survey views BRIC markets
  • Ono Pharma buys Japanese rights to two cancer drugs in $340 million deal with Onyx
  • GlaxoSmithKline sells Croatian research center to Galapagos, names new CFO and enters supply deal with Lonza; EMEA update on Avandia and Pandemrix
  • Wyeth/Pfizer accused of using ghostwritten articles to overstate benefits of HRT
  • China’s liver cancer drug market forecast to nearly triple to $144 million in 2014
  • International sales rep quality survey views BRIC markets

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2010 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS